Program
Arginine
Also written as “8% arginine + Zinc toothpaste”, “arginine/lysine” and “L Arginine”.
Its studies are mostly in Dental Caries · Dentin Sensitivity · Gastro-enteropancreatic neuroendocrine tumor · Peripheral Vascular Diseases · Peripheral Arterial Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmolive | 31 open or running | phase 3since Jun 18, 2026 | Feb 4, 2015 | none ahead |
| POLYSAN Scientific & Technological Pharmaceutical | 20 open or running | phase 2since Mar 1, 2019 | Jan 16, 2017 | none ahead |
| Novartis | 10 open or running | phase 4since Aug 20, 2020 | Aug 20, 2020 | none ahead |
| Pfizer | 10 open or running | no phasesince Jan 18, 2006 | Jan 18, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2006First study: no phase study in Diabetes MellitusNew to PfizerPfizer · NCT00280085 · 29 enrolled · United States
- Feb 4, 2015Colgate Palmolive's first study: phase 2 study in Dental CariesNew to Colgate PalmoliveColgate Palmolive · NCT02388178
- Jan 16, 2017POLYSAN Scientific & Technological Pharmaceutical's first study: phase 1 study in Peripheral Vascular DiseasesNew to POLYSAN Scientific & Technological PharmaceuticalPOLYSAN Scientific & Technological Pharmaceutical · NCT03028285 · 48 enrolled · Russian Federation
- Mar 1, 2019Phase 2 study in Peripheral Arterial DiseasePOLYSAN Scientific & Technological Pharmaceutical · NCT03861416 · 360 enrolled · Russian Federation
- Aug 20, 2020Novartis's first study: phase 4 study in Gastro-enteropancreatic neuroendocrine tumorNew to NovartisNovartis · NCT04524442 · 42 enrolled · Italy, Netherlands, Poland and more
- Dec 13, 2023Phase 1 study in Dental CariesColgate Palmolive · NCT06182267 · 29 enrolled · United States
- Jun 18, 2026Phase 3 study in Dentin SensitivityPhase 3 reachedColgate Palmolive · NCT07664592 · 132 planned · Brazil
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07664592Dentin Sensitivity · Brazil | 3 | Recruiting | Colgate Palmolive | Sep 2026 | 132 |
| NCT06182267Dental Caries · United States | 1 | Completed | Colgate Palmolive | Dec 22, 2023 | 29 |
| NCT04524442Gastro-enteropancreatic neuroendocrine tumor · Italy, Netherlands, Poland and more | 4 | Completed | Novartis | Nov 18, 2023 | 42 |
| NCT03861416Peripheral Arterial Disease · Russian Federation | 2 | Completed | POLYSAN Scientific & Technological Pharmaceutical | Sep 13, 2019 | 360 |
| NCT03028285Peripheral Vascular Diseases · Russian Federation | 1 | Completed | POLYSAN Scientific & Technological Pharmaceutical | Jan 19, 2017 | 48 |
| NCT02388178Dental Caries | 2 | Withdrawn | Colgate Palmolive | Jul 2015 | 0 |
| NCT00280085Diabetes Mellitus · United States | – | Terminated | Pfizer | 29 |
How it is read
Names in the registry
- “8% arginine + Zinc toothpaste”, 1 entry
- “arginine/lysine”, 1 entry
- “L Arginine”, 1 entry
- “Experimental toothpaste containing fluoride and amino acid (arginine)”, 1 entry
- “arginine sodium succinate”, 1 entry
Conditions, from the studies’ own filings
- Dental Caries, 2 studies
- Dentin Sensitivity, 1 study
- Gastro-enteropancreatic neuroendocrine tumor, 1 study
- Peripheral Vascular Diseases, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.